<p>Coppell Advisory Solutions LLC 在最近向證券交易委員會（SEC）提交的文件中表示，在第二季度將其在安進公司（NASDAQ:AMGN - 免費報告）的持股減少了 67.3%。該公司在季度內出售了 10,090 股後，持有 4,906 股該醫療研究公司的股票。Coppell Advisory Solutions LLC 在安進的持股在最近的報告期末價值為 1,360,000 美元。</p>
<ul>
<li>5 個醫療保健公司值得關注，因為行業輪動正在全面展開</li>
</ul>
<p>其他一些機構投資者最近也調整了對該公司的持股。B. Riley Wealth Advisors Inc. 在第二季度購買了安進的新股份，價值約為 1,647,000 美元。Newbridge Financial Services Group Inc. 在第二季度將其在安進的持股增加了 50.2%。Newbridge Financial Services Group Inc. 目前持有 640 股該醫療研究公司的股票，價值 179,000 美元，此前在上個季度增持了 214 股。Advisory Services Network LLC 在第二季度將其在安進的持股增加了 16.5%。Advisory Services Network LLC 目前持有 31,648 股該醫療研究公司的股票，價值 9,339,000 美元，此前在上個季度增持了 4,491 股。Anchor Investment Management LLC 在第二季度將其在安進的持股增加了 6.5%。Anchor Investment Management LLC 目前持有 4,942 股該醫療研究公司的股票，價值 1,380,000 美元，此前在上個季度增持了 301 股。最後，Asset Dedication LLC 在第二季度將其在安進的持股增加了 3.6%。Asset Dedication LLC 目前持有 11,617 股該醫療研究公司的股票，價值 3,244,000 美元，此前在上個季度增持了 409 股。76.50% 的股票目前由機構投資者持有。</p>
<h2>安進的內部買賣</h2>
<p>在相關消息中，SVP Rachna Khosla 於 11 月 12 日（星期三）出售了 890 股公司的股票。股票以平均價格 336.24 美元出售，總價值為 299,253.60 美元。交易完成後，這位高級副總裁持有 7,082 股公司股票，價值約為 2,381,251.68 美元。這代表其持股減少了 11.16%。該出售在向證券交易委員會的文件中披露，該文件可通過 SEC 網站訪問。此外，EVP Murdo Gordon 於 11 月 12 日（星期三）出售了 6,879 股股票。股票以平均價格 336.83 美元出售，總交易額為 2,317,053.57 美元。交易完成後，這位執行副總裁直接持有 41,923 股公司股票，價值約為 14,120,924.09 美元。這代表其持股減少了 14.10%。該出售的 SEC 文件提供了更多信息。在過去的九十天裏，內部人士共出售了 10,908 股公司股票，價值 3,674,966 美元。內部人士持有公司股票的比例為 0.76%。</p>
<h2>安進股票上漲 0.1%</h2>
<ul>
<li>安進股票：在盈利超預期後，新的歷史高點即將到來</li>
</ul>
<p>安進股票在週五開盤價為 317.74 美元。該股票的 50 日簡單移動平均線為 316.12 美元，200 日簡單移動平均線為 298.78 美元。該股票的市值為 1711 億美元，市盈率為 24.55，市盈增長比率為 2.87，貝塔係數為 0.45。該公司的債務與股本比率為 5.45，速動比率為 0.99，流動比率為 1.28。安進公司的 52 周低點為 253.30 美元，52 周高點為 346.38 美元。</p>
<p>安進（NASDAQ:AMGN - 獲取免費報告）最近於 11 月 4 日（星期二）發佈了季度財報。該醫療研究公司報告每股收益（EPS）為 5.64 美元，超出分析師一致預期的 5.01 美元，超出幅度為 0.63 美元。安進的股本回報率為 162.59%，淨利潤率為 19.47%。該公司在本季度的收入為 95.6 億美元，而分析師預期為 89.8 億美元。去年同期，該公司每股收益為 5.58 美元。該公司的收入同比增長 12.4%。安進已將其 2025 財年的指引設定為每股收益 20.600-21.400 美元。分析師預計安進公司今年的每股收益為 20.62 美元。</p>
<h2>安進增加股息</h2>
<ul>
<li>皇家制藥如何在不承擔生物技術最大風險的情況下創造現金</li>
</ul>
<p>該公司最近還披露了季度股息，將於 3 月 6 日（星期五）支付。2 月 13 日（星期五）的股東將獲得每股 2.52 美元的股息。這相當於年化股息 10.08 美元，收益率為 3.2%。這比安進之前的季度股息 2.38 美元有所增加。該股息的除息日期為 2 月 13 日（星期五）。安進的股息支付比率（DPR）目前為 73.57%。</p>
<h2>分析師設定新的價格目標</h2>
<p>一些研究公司最近對 AMGN 進行了評估。Truist Financial 在 11 月 24 日（星期一）發佈的研究報告中開始覆蓋安進的股票。他們對該公司給予了 “持有” 評級，並設定了 318.00 美元的目標價格。滙豐銀行在週三重申了 “買入” 評級，並設定了 425.00 美元的目標價格。Weiss Ratings 在 10 月 8 日（星期三）的研究報告中將安進的評級從 “持有（c+）” 上調至 “買入（b-）”。摩根士丹利在週五將安進的目標價格從 329.00 美元下調至 304.00 美元，並對該公司設定了 “同等權重” 評級。最後，Raymond James Financial 在 9 月 3 日（星期三）的研究報告中開始覆蓋安進。他們對該股票設定了 “市場表現” 評級。一位分析師對該股票給予了強烈買入評級，十位分析師給予了買入評級，十位分析師給予了持有評級，一位分析師給予了賣出評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “適度買入”，共識目標價格為 332.85 美元。</p>
<p><strong>查看我們關於安進的最新研究報告</strong></p>
<h2>安進公司簡介</h2>
<p>（免費報告）</p>
<p>安進公司在全球範圍內發現、開發、生產和交付人類治療藥物。公司的主要產品包括用於治療斑塊型銀屑病、類風濕性關節炎和銀屑病關節炎的恩利昔（Enbrel）；用於治療成人斑塊型銀屑病、銀屑病關節炎和與貝赫切特病相關的口腔潰瘍的 Otezla；用於治療絕經後女性骨質疏鬆症的 Prolia；用於預防骨骼相關事件的 XGEVA；可降低心肌梗死、中風和冠狀動脈再血管化風險的 Repatha；用於治療免疫性血小板減少症患者的 Nplate；用於治療複發性或難治性多發性骨髓瘤患者的 KYPROLIS；用於治療紅細胞數量低於正常水平和貧血的 Aranesp；用於治療絕經後男性和女性骨質疏鬆症的 EVENITY；用於治療野生型 RAS 轉移性結直腸癌患者的 Vectibix；用於治療急性淋巴細胞白血病患者的 BLINCYTO；用於治療甲狀腺眼病的 TEPEZZA；以及用於治療慢性難治性痛風的 KRYSTEXXA。</p>
<h2>另請參見</h2>
<ul>
<li>我們更看好的五隻股票超過安進</li>
<li>零售投資者如何交易多倫多證券交易所（TSX）？</li>
<li>迪士尼的 10 億美元交易將其魔力帶入 OpenAI</li>
<li>這些液化天然氣股票是否準備迎來反彈？</li>
<li>為什麼亞馬遜可能在幾周內成為 300 美元的股票</li>
<li>3 只雜貨股票證明它們仍然是必需品</li>
<li>Adobe 在財報後獲得提振：長期前景看漲</li>
</ul>
<p><strong>想知道其他對 AMGN 持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取安進公司（NASDAQ:AMGN - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在安進嗎？</h2>
<p>在考慮安進之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而安進並不在名單上。</p>
<p>雖然安進目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

安進

<p>Coppell Advisory Solutions LLC 在第二季度減少了對安進（Amgen Inc.）的持股比例，降幅為 67.3%，目前持有價值 136 萬美元的股份。其他機構投資者也調整了他們的持倉，其中一些增加了持股。內部交易方面，SVP Rachna Khosla 和 EVP Murdo Gordon 進行了股票出售。安進的股票表現略有上升，最近公佈的財報超出預期，並宣佈了分紅。公司報告了強勁的財務數據，年同比收入增長 12.4%，並對盈利前景持積極態度</p>

<p>Coppell Advisory Solutions LLC decreased its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 67.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,906 shares of the medical research company's stock after selling 10,090 shares during the quarter. Coppell Advisory Solutions LLC's holdings in Amgen were worth $1,360,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Coppell Advisory Solutions LLC 在最近向證券交易委員會（SEC）提交的文件中表示，在第二季度將其在安進公司（NASDAQ:AMGN - 免費報告）的持股減少了 67.3%。該公司在季度內出售了 10,090 股後，持有 4,906 股該醫療研究公司的股票。Coppell Advisory Solutions LLC 在安進的持股在最近的報告期末價值為 1,360,000 美元。</p>
</div><ul>
<li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li>
</ul>
<div class="lb-trans"><ul>
<li>5 個醫療保健公司值得關注，因為行業輪動正在全面展開</li>
</ul>
</div><p>A number of other institutional investors also recently modified their holdings of the company. B. Riley Wealth Advisors Inc. bought a new position in shares of Amgen during the second quarter worth about $1,647,000. Newbridge Financial Services Group Inc. boosted its position in Amgen by 50.2% during the 2nd quarter. Newbridge Financial Services Group Inc. now owns 640 shares of the medical research company's stock worth $179,000 after acquiring an additional 214 shares during the last quarter. Advisory Services Network LLC grew its stake in shares of Amgen by 16.5% during the 2nd quarter. Advisory Services Network LLC now owns 31,648 shares of the medical research company's stock worth $9,339,000 after acquiring an additional 4,491 shares in the last quarter. Anchor Investment Management LLC raised its holdings in shares of Amgen by 6.5% in the second quarter. Anchor Investment Management LLC now owns 4,942 shares of the medical research company's stock valued at $1,380,000 after purchasing an additional 301 shares during the last quarter. Finally, Asset Dedication LLC raised its holdings in shares of Amgen by 3.6% in the second quarter. Asset Dedication LLC now owns 11,617 shares of the medical research company's stock valued at $3,244,000 after purchasing an additional 409 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他一些機構投資者最近也調整了對該公司的持股。B. Riley Wealth Advisors Inc. 在第二季度購買了安進的新股份，價值約為 1,647,000 美元。Newbridge Financial Services Group Inc. 在第二季度將其在安進的持股增加了 50.2%。Newbridge Financial Services Group Inc. 目前持有 640 股該醫療研究公司的股票，價值 179,000 美元，此前在上個季度增持了 214 股。Advisory Services Network LLC 在第二季度將其在安進的持股增加了 16.5%。Advisory Services Network LLC 目前持有 31,648 股該醫療研究公司的股票，價值 9,339,000 美元，此前在上個季度增持了 4,491 股。Anchor Investment Management LLC 在第二季度將其在安進的持股增加了 6.5%。Anchor Investment Management LLC 目前持有 4,942 股該醫療研究公司的股票，價值 1,380,000 美元，此前在上個季度增持了 301 股。最後，Asset Dedication LLC 在第二季度將其在安進的持股增加了 3.6%。Asset Dedication LLC 目前持有 11,617 股該醫療研究公司的股票，價值 3,244,000 美元，此前在上個季度增持了 409 股。76.50% 的股票目前由機構投資者持有。</p>
</div><h2>Insider Buying and Selling at Amgen</h2>
<div class="lb-trans"><h2>安進的內部買賣</h2>
</div><p>In related news, SVP Rachna Khosla sold 890 shares of the company's stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total value of $299,253.60. Following the transaction, the senior vice president owned 7,082 shares in the company, valued at approximately $2,381,251.68. This represents a 11.16% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, EVP Murdo Gordon sold 6,879 shares of the stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the completion of the transaction, the executive vice president directly owned 41,923 shares in the company, valued at approximately $14,120,924.09. This represents a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 10,908 shares of company stock worth $3,674,966 over the last ninety days. Insiders own 0.76% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，SVP Rachna Khosla 於 11 月 12 日（星期三）出售了 890 股公司的股票。股票以平均價格 336.24 美元出售，總價值為 299,253.60 美元。交易完成後，這位高級副總裁持有 7,082 股公司股票，價值約為 2,381,251.68 美元。這代表其持股減少了 11.16%。該出售在向證券交易委員會的文件中披露，該文件可通過 SEC 網站訪問。此外，EVP Murdo Gordon 於 11 月 12 日（星期三）出售了 6,879 股股票。股票以平均價格 336.83 美元出售，總交易額為 2,317,053.57 美元。交易完成後，這位執行副總裁直接持有 41,923 股公司股票，價值約為 14,120,924.09 美元。這代表其持股減少了 14.10%。該出售的 SEC 文件提供了更多信息。在過去的九十天裏，內部人士共出售了 10,908 股公司股票，價值 3,674,966 美元。內部人士持有公司股票的比例為 0.76%。</p>
</div><h2>Amgen Trading Up 0.1%</h2>
<div class="lb-trans"><h2>安進股票上漲 0.1%</h2>
</div><ul>
<li>Amgen Stock: New All-Time Highs Ahead After Earnings Beat</li>
</ul>
<div class="lb-trans"><ul>
<li>安進股票：在盈利超預期後，新的歷史高點即將到來</li>
</ul>
</div><p>Amgen stock opened at $317.74 on Friday. The stock has a 50-day simple moving average of $316.12 and a 200 day simple moving average of $298.78. The stock has a market capitalization of $171.10 billion, a P/E ratio of 24.55, a PEG ratio of 2.87 and a beta of 0.45. The company has a debt-to-equity ratio of 5.45, a quick ratio of 0.99 and a current ratio of 1.28. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.38.</p>
<div class="lb-trans"><p>安進股票在週五開盤價為 317.74 美元。該股票的 50 日簡單移動平均線為 316.12 美元，200 日簡單移動平均線為 298.78 美元。該股票的市值為 1711 億美元，市盈率為 24.55，市盈增長比率為 2.87，貝塔係數為 0.45。該公司的債務與股本比率為 5.45，速動比率為 0.99，流動比率為 1.28。安進公司的 52 周低點為 253.30 美元，52 周高點為 346.38 美元。</p>
</div><p>Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.01 by $0.63. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The company had revenue of $9.56 billion during the quarter, compared to analysts' expectations of $8.98 billion. During the same period last year, the firm posted $5.58 earnings per share. The business's revenue was up 12.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.</p>
<div class="lb-trans"><p>安進（NASDAQ:AMGN - 獲取免費報告）最近於 11 月 4 日（星期二）發佈了季度財報。該醫療研究公司報告每股收益（EPS）為 5.64 美元，超出分析師一致預期的 5.01 美元，超出幅度為 0.63 美元。安進的股本回報率為 162.59%，淨利潤率為 19.47%。該公司在本季度的收入為 95.6 億美元，而分析師預期為 89.8 億美元。去年同期，該公司每股收益為 5.58 美元。該公司的收入同比增長 12.4%。安進已將其 2025 財年的指引設定為每股收益 20.600-21.400 美元。分析師預計安進公司今年的每股收益為 20.62 美元。</p>
</div><h2>Amgen Increases Dividend</h2>
<div class="lb-trans"><h2>安進增加股息</h2>
</div><ul>
<li>How Royalty Pharma Prints Cash Without Biotech's Biggest Risks</li>
</ul>
<div class="lb-trans"><ul>
<li>皇家制藥如何在不承擔生物技術最大風險的情況下創造現金</li>
</ul>
</div><p>The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 3.2%. This is a positive change from Amgen's previous quarterly dividend of $2.38. The ex-dividend date of this dividend is Friday, February 13th. Amgen's dividend payout ratio (DPR) is presently 73.57%.</p>
<div class="lb-trans"><p>該公司最近還披露了季度股息，將於 3 月 6 日（星期五）支付。2 月 13 日（星期五）的股東將獲得每股 2.52 美元的股息。這相當於年化股息 10.08 美元，收益率為 3.2%。這比安進之前的季度股息 2.38 美元有所增加。該股息的除息日期為 2 月 13 日（星期五）。安進的股息支付比率（DPR）目前為 73.57%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的價格目標</h2>
</div><p>A number of research firms recently weighed in on AMGN. Truist Financial started coverage on shares of Amgen in a research report on Monday, November 24th. They issued a &#34;hold&#34; rating and a $318.00 target price for the company. HSBC restated a &#34;buy&#34; rating and set a $425.00 price objective on shares of Amgen in a research note on Wednesday. Weiss Ratings raised Amgen from a &#34;hold (c+)&#34; rating to a &#34;buy (b-)&#34; rating in a research report on Wednesday, October 8th. Morgan Stanley reduced their price target on Amgen from $329.00 to $304.00 and set an &#34;equal weight&#34; rating for the company in a research report on Friday. Finally, Raymond James Financial began coverage on Amgen in a research report on Wednesday, September 3rd. They set a &#34;market perform&#34; rating on the stock. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $332.85.</p>
<div class="lb-trans"><p>一些研究公司最近對 AMGN 進行了評估。Truist Financial 在 11 月 24 日（星期一）發佈的研究報告中開始覆蓋安進的股票。他們對該公司給予了 “持有” 評級，並設定了 318.00 美元的目標價格。滙豐銀行在週三重申了 “買入” 評級，並設定了 425.00 美元的目標價格。Weiss Ratings 在 10 月 8 日（星期三）的研究報告中將安進的評級從 “持有（c+）” 上調至 “買入（b-）”。摩根士丹利在週五將安進的目標價格從 329.00 美元下調至 304.00 美元，並對該公司設定了 “同等權重” 評級。最後，Raymond James Financial 在 9 月 3 日（星期三）的研究報告中開始覆蓋安進。他們對該股票設定了 “市場表現” 評級。一位分析師對該股票給予了強烈買入評級，十位分析師給予了買入評級，十位分析師給予了持有評級，一位分析師給予了賣出評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “適度買入”，共識目標價格為 332.85 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on Amgen</strong></p>
<div class="lb-trans"><p><strong>查看我們關於安進的最新研究報告</strong></p>
</div><h2>Amgen Company Profile</h2>
<div class="lb-trans"><h2>安進公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.</p>
<div class="lb-trans"><p>安進公司在全球範圍內發現、開發、生產和交付人類治療藥物。公司的主要產品包括用於治療斑塊型銀屑病、類風濕性關節炎和銀屑病關節炎的恩利昔（Enbrel）；用於治療成人斑塊型銀屑病、銀屑病關節炎和與貝赫切特病相關的口腔潰瘍的 Otezla；用於治療絕經後女性骨質疏鬆症的 Prolia；用於預防骨骼相關事件的 XGEVA；可降低心肌梗死、中風和冠狀動脈再血管化風險的 Repatha；用於治療免疫性血小板減少症患者的 Nplate；用於治療複發性或難治性多發性骨髓瘤患者的 KYPROLIS；用於治療紅細胞數量低於正常水平和貧血的 Aranesp；用於治療絕經後男性和女性骨質疏鬆症的 EVENITY；用於治療野生型 RAS 轉移性結直腸癌患者的 Vectibix；用於治療急性淋巴細胞白血病患者的 BLINCYTO；用於治療甲狀腺眼病的 TEPEZZA；以及用於治療慢性難治性痛風的 KRYSTEXXA。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另請參見</h2>
</div><ul>
<li>Five stocks we like better than Amgen</li>
<li>How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?</li>
<li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li>
<li>Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?</li>
<li>Why Amazon Could Be a $300 Stock Within Weeks</li>
<li>3 Grocery Stocks That Are Proving They Are Still Essential</li>
<li>Adobe Gets Post-Earnings Lift: Long-Term Outlook Favors Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過安進</li>
<li>零售投資者如何交易多倫多證券交易所（TSX）？</li>
<li>迪士尼的 10 億美元交易將其魔力帶入 OpenAI</li>
<li>這些液化天然氣股票是否準備迎來反彈？</li>
<li>為什麼亞馬遜可能在幾周內成為 300 美元的股票</li>
<li>3 只雜貨股票證明它們仍然是必需品</li>
<li>Adobe 在財報後獲得提振：長期前景看漲</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding AMGN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他對 AMGN 持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取安進公司（NASDAQ:AMGN - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AMGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Amgen Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在安進嗎？</h2>
</div><p>Before you consider Amgen, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮安進之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而安進並不在名單上。</p>
</div><p>While Amgen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然安進目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Coppell Advisory Solutions LLC 持有安進公司價值 136 萬美元的股份